Form 4: Alector CEO Sells Shares for Tax Obligations

Alector, Inc. CEO Arnon Rosenthal sold 104,347 shares of common stock at a weighted average price of $1.1196 to cover tax obligations from restricted stock unit vesting.

Summary

• Arnon Rosenthal, Chief Executive Officer and Director of Alector, Inc. (ALEC), reported a sale of common stock.
• The transaction involved the disposition of 104,347 shares of Alector common stock.
• The shares were sold on December 3, 2025, at a weighted average price of $1.1196 per share.
• The sale was executed to satisfy tax obligations arising from the vesting of restricted stock units (RSUs).
• Following the transaction, Arnon Rosenthal directly beneficially owns 2,420,040 shares of common stock.
• Additionally, he indirectly beneficially owns 1,972,875 shares through The Rosenthal Family Revocable Trust and 652,500 shares each through the Adi Rosenthal 2007 Trust, Noam Rosenthal 2007 Trust, and Shani Rosenthal 2007 Trust, totaling 3,930,375 indirect shares.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations from RSU vesting, which is a neutral event. It does not reflect a change in management's confidence or the company's fundamentals.

Positives

• The transaction was non-discretionary, specifically to cover tax obligations from RSU vesting, indicating a pre-planned event rather than a discretionary sale based on market outlook.

Negatives

• An insider sale, even for tax purposes, reduces the CEO's direct equity stake in the company.
• The sale occurred at a relatively low weighted average price of $1.1196 per share.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.

Industry Context

Insider transactions, particularly those related to tax obligations from RSU vesting, are common across all industries, including biotechnology. This type of transaction is generally considered routine and not indicative of specific industry trends or competitive positioning.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: May perceive a slight negative signal due to an insider selling shares, although the stated reason (tax obligations) mitigates this concern.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by the CEO to cover tax obligations associated with RSU vesting. Such transactions are common and typically do not reflect a change in the company's fundamental outlook or management's long-term confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Alector, ALEC, Arnon Rosenthal, CEO, Insider Trading, Form 4, Stock Sale, Tax Obligations, RSU Vesting, Biotechnology